HDL function as a predictor of coronary heart disease events: time to re-assess the HDL hypothesis?
暂无分享，去创建一个
[1] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[2] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[3] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[4] John Spertus,et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.
[5] Markus Abt,et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[6] S. Hazen,et al. Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[7] P. Barter,et al. Cardioprotective functions of HDLs1 , 2014, Journal of Lipid Research.
[8] A. Khera,et al. HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.
[9] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.
[10] D. Rader,et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study , 2015, The lancet. Diabetes & endocrinology.